Tango Therapeutics (TNGX)
(Delayed Data from NSDQ)
$7.14 USD
+0.23 (3.33%)
Updated Oct 16, 2024 04:00 PM ET
After-Market: $7.14 0.00 (0.00%) 5:34 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
Brokerage Reports
0 items in cart
Tango Therapeutics, Inc. [TNGX]
Reports for Purchase
Showing records 1 - 20 ( 51 total )
Company: Tango Therapeutics, Inc.
Industry: Unclassified
The Wedbush Monthly Check-Up: October 2024
Provider: Wedbush Securities Inc.
Analyst: Research Department
Company: Tango Therapeutics, Inc.
Industry: Unclassified
Company: Tango Therapeutics, Inc.
Industry: Unclassified
AMG 193''s ESMO Abstract Potentially Increases the Risk for TNG908/TNG462; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Tango Therapeutics, Inc.
Industry: Unclassified
Company: Tango Therapeutics, Inc.
Industry: Unclassified
Company: Tango Therapeutics, Inc.
Industry: Unclassified
2Q24 Financials; TNG908 and TNG462 Clinical Updates in 2H24; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Tango Therapeutics, Inc.
Industry: Unclassified
Company: Tango Therapeutics, Inc.
Industry: Unclassified
TNG348 Development Discontinued; Modulating PT to $13
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Tango Therapeutics, Inc.
Industry: Unclassified
TNG348 A No-Go; Remain Confident in PRMT5 Franchise
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Company: Tango Therapeutics, Inc.
Industry: Unclassified
Q1 Financials; Execution Across Pipeline, PRMT5 Program Update in 2H:24
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Company: Tango Therapeutics, Inc.
Industry: Unclassified
We Eagerly Await Initial TNG908/TNG462 Data; 1Q24 Financials; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Tango Therapeutics, Inc.
Industry: Unclassified
We Eagerly Await Initial TNG908 Data; 4Q23 Financials; Adjusting PT to $17
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Tango Therapeutics, Inc.
Industry: Unclassified
Company: Tango Therapeutics, Inc.
Industry: Unclassified
2024 Top Picks: Seeing Important Turnaround Year While Watching the Macro
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: Tango Therapeutics, Inc.
Industry: Unclassified
2024 Top Picks: Seeing Important Turnaround Year While Watching the Macro
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: Tango Therapeutics, Inc.
Industry: Unclassified
Company: Tango Therapeutics, Inc.
Industry: Unclassified
Company: Tango Therapeutics, Inc.
Industry: Unclassified
Company: Tango Therapeutics, Inc.
Industry: Unclassified
Optimized Entry and Exit Levels for TNGX 112223
Provider: Stock Traders Daily
Analyst: Research Department